Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.55 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.55 |
| ▸ | CA2 | P00918 | 1/20 | 0.55 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.55 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | HPGD | P15428 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | RAD52 | P43351 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7016460 | 0.90 | SMN1; SMN2 (0.57) | PARP1PARP10CA1CA2PARP2 | |
| SCHEMBL3277227 | 0.90 | ALDH1A1 (0.62) | PARP1PARP10CA1CA2PARP2 | |
| SCHEMBL1807116 | 0.86 | PARP1 (0.53) | PARP1PARP10CA1CA2PARP2 | |
| SCHEMBL7456188 | 0.86 | MTNR1A (0.54) | PARP1PARP10CA1CA2PARP2 | |
| SCHEMBL16495950 | 0.86 | CA1 (0.51) | PARP1PARP10CA1CA2PARP2 | |
| SCHEMBL551750 | 0.84 | NPC1 (0.56) | PARP1PARP10CA1CA2PARP2 | |
| SCHEMBL1807278 | 0.84 | PARP1 (0.52) | PARP1PARP10CA1CA2PARP2 | |
| SCHEMBL1034025 | 0.84 | ALDH1A1 (0.68) | PARP10CA1CA2NPC1RAB9A | |
| SCHEMBL3343162 | 0.84 | PARP1 (0.52) | PARP1PARP10CA1CA2PARP2 | |
| SCHEMBL2855495 | 0.84 | KDM4E (0.55) | PARP1PARP10CA1CA2PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111004188-B | NS3/4A protease inhibitor intermediate, and synthetic method and application thereof | 安徽红杉生物医药科技有限公司 | 2021-04-20 | — | — | CN | claimed |
| CN-111004188-A | NS3/4A protease inhibitor intermediate, and synthetic method and application thereof | 安徽红杉生物医药科技有限公司 | 2020-04-14 | — | — | CN | claimed |
| CN-117538404-A | Annular RNA detection method based on capillary gel electrophoresis | 杭州明德生物医药技术有限公司 | 2024-02-09 | — | — | CN | disclosed |
| CN-111004188-B | NS3/4A protease inhibitor intermediate, and synthetic method and application thereof | 安徽红杉生物医药科技有限公司 | 2021-04-20 | — | — | CN | disclosed |
| CN-111004188-A | NS3/4A protease inhibitor intermediate, and synthetic method and application thereof | 安徽红杉生物医药科技有限公司 | 2020-04-14 | — | — | CN | disclosed |
| US-7700552-B2 | Macrocyclic inhibitors of hepatitis C virus | MEDIVIR AB (SE) | 2010-04-20 | — | — | US | disclosed |
| US-7659245-B2 | Macrocylic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD (IE) | 2010-02-09 | — | — | US | disclosed |
| EP-1912981-B1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARM LTD (IE) | 2010-01-20 | — | — | EP | disclosed |
| US-20090118312-A1 | Macrocylic Inhibitors of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2009-05-07 | — | — | US | disclosed |
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | MEDIVIR AB (SE) | 2009-01-22 | — | — | US | disclosed |
| EP-1912981-A2 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | Tibotec Pharmaceuticals Ltd. (IE) | 2008-04-23 | — | — | EP | disclosed |
| EP-1910347-A2 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | MEDIVIR AB (SE) | 2008-04-16 | — | — | EP | disclosed |
| EP-1881002-A1 | HCV NS-3 serine protease inhibitors | Tibotec Pharmaceuticals Ltd. (IE) | 2008-01-23 | — | — | EP | disclosed |
| EP-1881001-A1 | HCV NS-3 serine protease inhibitors | Tibotec Pharmaceuticals Ltd. (IE) | 2008-01-23 | — | — | EP | disclosed |
| WO-2007017144-A2 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | MEDIVIR AB (SE) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007014927-A2 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
| EP-1174428-B1 | Process for the preparation of uretdione polyisocyanates with improved monomer stability | BAYER AG (DE) | 2003-10-29 | — | — | EP | disclosed |
| US-6444778-B1 | DIISOCYANATES DIMERIZED USING TERTIARY PHOSPHINE CATALYST AND UREA OR AMIDE STABILIZERS; HIGH TEMPERATURE STORAGE STABLE CROSSLINKER FOR TWO-COMPONENT POLYURETHANE COATINGS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-09-03 | — | — | US | disclosed |
| US-20020028930-A1 | Process for the production of uretdione polyisocyanates with improved monomer stability | BAYER AKTEINGESELLSCHAFT (DE) | 2002-03-07 | — | — | US | disclosed |
| EP-1174428-A2 | Process for the preparation of uretdione polyisocyanates with improved monomer stability | Bayer Aktiengesellschaft (DE) | 2002-01-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | CTRC, NOX3, HAVCR2 | PARP1 2800/4885PARP10 3318/4885CA1 668/4885 |
| US-20020028930-A1 | Process for the production of uretdione polyisocyanates with improved monomer stability | UROD, PUF60, UFM1 | PARP1 653/4885PARP10 375/4885CA1 4043/4885 |
| US-20090118312-A1 | Macrocylic Inhibitors of Hepatitis C Virus | CBR1, HAVCR2, AOC1 | PARP1 988/4885PARP10 3112/4885CA1 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.